Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 11/2013

01.11.2013 | Retinal Disorders

Long-term course in type 2 idiopathic macular telangiectasia

verfasst von: Tobias Meyer-ter-Vehn, Sina Herzog, Marc Schargus, Winfried Göbel, Rainer Guthoff

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 11/2013

Einloggen, um Zugang zu erhalten

Abstract

Introduction

To study the long-term course in patients with idiopathic macular telangiectasia and report the effect of anti VEGF and laser treatment.

Methods

A retrospective case series of 19 patients/38 eyes with symptomatic type 2 idiopathic macular telangiectasia was performed. Six eyes received intravitreal injections of bevacizumab (1–3 injections), four eyes received focal laser treatment. Follow up examinations comprised visual acuity, biomicroscopy, fluorescein angiography and assessment of macular morphology and thickness by time and spectral-domain optical coherence tomography (OCT).

Results

Mean follow-up time was 81 months (range 15–188 months) – the median added up to 80 months. Visual outcome at final visit varied substantially (20/200–20/20). On average visual acuity decreased 1,2 lines (range −0,5 to 6) by 3 years, 2 lines (range −0,5 to 7) by 5 years and 4,1 lines (range 0 to 12) by 10 years. Development of choroidal neovascularisation was observed in only one eye. There was no significant difference in visual acuity between eyes receiving no treatment, intravitreal bevacizumab or laser treatment after 3 and 5 years. Morphological studies by OCT revealed typical changes with retinal atrophy and intraretinal cysts. Visual acuity correlated with the eccentricity of the main manifestation–visual preservation was associated with mainly extrafoveal disease manifestation.

Discussion

Type 2 idiopathic macular telangiectasia is a chronic, often slowly progressing macular disease leading to retinal atrophy and visual impairment over decades. Thorough knowledge about the long term course of this disease is necessary to evaluate possible therapeutic options in the long run.
Literatur
2.
Zurück zum Zitat Charbel Issa P, Holz FG, Scholl HP (2007) Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Ophthalmology 114:1736–1742PubMedCrossRef Charbel Issa P, Holz FG, Scholl HP (2007) Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Ophthalmology 114:1736–1742PubMedCrossRef
3.
Zurück zum Zitat Surguch V, Gamulescu MA, Gabel VP (2007) Optical coherence tomography findings in idiopathic juxtafoveal retinal telangiectasis. Graefes Arch Clin Exp Ophthalmol 245:783–788PubMedCrossRef Surguch V, Gamulescu MA, Gabel VP (2007) Optical coherence tomography findings in idiopathic juxtafoveal retinal telangiectasis. Graefes Arch Clin Exp Ophthalmol 245:783–788PubMedCrossRef
4.
Zurück zum Zitat Gaudric A, Ducos de Lahitte G, Cohen SY, Massin P, Haouchine B (2006) Optical coherence tomography in group 2A idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol 124:1410–1419PubMedCrossRef Gaudric A, Ducos de Lahitte G, Cohen SY, Massin P, Haouchine B (2006) Optical coherence tomography in group 2A idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol 124:1410–1419PubMedCrossRef
5.
Zurück zum Zitat Helb HM, Charbel Issa P, van der Veen RL, Berendschot TT, Scholl HP, Holz FG (2008) Abnormal macular pigment distribution in type 2 idiopathic macular telangiectasia. Retina 28:808–816PubMedCrossRef Helb HM, Charbel Issa P, van der Veen RL, Berendschot TT, Scholl HP, Holz FG (2008) Abnormal macular pigment distribution in type 2 idiopathic macular telangiectasia. Retina 28:808–816PubMedCrossRef
6.
Zurück zum Zitat Charbel Issa P, Finger RP, Helb HM, Holz FG, Scholl HP (2008) A new diagnostic approach in patients with type 2 macular telangiectasia: confocal reflectance imaging. Acta Ophthalmol 86:464–465PubMedCrossRef Charbel Issa P, Finger RP, Helb HM, Holz FG, Scholl HP (2008) A new diagnostic approach in patients with type 2 macular telangiectasia: confocal reflectance imaging. Acta Ophthalmol 86:464–465PubMedCrossRef
7.
Zurück zum Zitat Charbel Issa P, Helb HM, Rohrschneider K, Holz FG, Scholl HP (2007) Microperimetric assessment of patients with type 2 idiopathic macular telangiectasia. Investig Ophthalmol Vis Sci 48:3788–3795CrossRef Charbel Issa P, Helb HM, Rohrschneider K, Holz FG, Scholl HP (2007) Microperimetric assessment of patients with type 2 idiopathic macular telangiectasia. Investig Ophthalmol Vis Sci 48:3788–3795CrossRef
8.
Zurück zum Zitat Finger RP, Charbel Issa P, Fimmers R, Holz FG, Rubin GS, Scholl HP (2009) Reading performance is reduced by parafoveal scotomas in patients with macular telangiectasia type 2. Investig Ophthalmol Vis Sci 50:1366–1370CrossRef Finger RP, Charbel Issa P, Fimmers R, Holz FG, Rubin GS, Scholl HP (2009) Reading performance is reduced by parafoveal scotomas in patients with macular telangiectasia type 2. Investig Ophthalmol Vis Sci 50:1366–1370CrossRef
9.
Zurück zum Zitat Yannuzzi LA, Bardal AM, Freund KB, Chen KJ, Eandi CM, Blodi B (2006) Idiopathic macular telangiectasia. Arch Ophthalmol 124:450–460PubMedCrossRef Yannuzzi LA, Bardal AM, Freund KB, Chen KJ, Eandi CM, Blodi B (2006) Idiopathic macular telangiectasia. Arch Ophthalmol 124:450–460PubMedCrossRef
10.
Zurück zum Zitat Park DW, Schatz H, McDonald HR, Johnson RN (1997) Grid laser photocoagulation for macular edema in bilateral juxtafoveal telangiectasis. Ophthalmology 104:1838–1846PubMedCrossRef Park DW, Schatz H, McDonald HR, Johnson RN (1997) Grid laser photocoagulation for macular edema in bilateral juxtafoveal telangiectasis. Ophthalmology 104:1838–1846PubMedCrossRef
11.
Zurück zum Zitat De Lahitte GD, Cohen SY, Gaudric A (2004) Lack of apparent short-term benefit of photodynamic therapy in bilateral, acquired, parafoveal telangiectasis without subretinal neovascularization. Am J Ophthalmol 138:892–894PubMedCrossRef De Lahitte GD, Cohen SY, Gaudric A (2004) Lack of apparent short-term benefit of photodynamic therapy in bilateral, acquired, parafoveal telangiectasis without subretinal neovascularization. Am J Ophthalmol 138:892–894PubMedCrossRef
12.
Zurück zum Zitat Charbel Issa P, Finger RP, Holz FG, Scholl HP (2008) Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Br J Ophthalmol 92:941–945PubMedCrossRef Charbel Issa P, Finger RP, Holz FG, Scholl HP (2008) Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Br J Ophthalmol 92:941–945PubMedCrossRef
13.
Zurück zum Zitat Charbel Issa P, Scholl HP, Holz FG (2007) Intravitreal bevacizumab for the treatment of type 2 idiopathic macular teleangiectasis. Retin Case Brief Rep 1:189–191CrossRef Charbel Issa P, Scholl HP, Holz FG (2007) Intravitreal bevacizumab for the treatment of type 2 idiopathic macular teleangiectasis. Retin Case Brief Rep 1:189–191CrossRef
14.
Zurück zum Zitat Kovach JL, Rosenfeld PJ (2009) Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II. Retina 29:27–32PubMedCrossRef Kovach JL, Rosenfeld PJ (2009) Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II. Retina 29:27–32PubMedCrossRef
15.
Zurück zum Zitat Matsumoto Y, Yuzawa M (2010) Intravitreal bevacizumab therapy for idiopathic macular telangiectasia. Jpn J Ophthalmol 54:320–324PubMedCrossRef Matsumoto Y, Yuzawa M (2010) Intravitreal bevacizumab therapy for idiopathic macular telangiectasia. Jpn J Ophthalmol 54:320–324PubMedCrossRef
16.
Zurück zum Zitat Matt G, Sacu S, Ahlers C, Schutze C, Dunavoelgyi R, Prager F, Pruente C, Schmidt-Erfurth U (2010) Thirty-month follow-up after intravitreal bevacizumab in progressive idiopathic macular telangiectasia type 2. Eye (Lond) 24:1535–1541CrossRef Matt G, Sacu S, Ahlers C, Schutze C, Dunavoelgyi R, Prager F, Pruente C, Schmidt-Erfurth U (2010) Thirty-month follow-up after intravitreal bevacizumab in progressive idiopathic macular telangiectasia type 2. Eye (Lond) 24:1535–1541CrossRef
17.
Zurück zum Zitat Charbel Issa P, Finger RP, Kruse K, Baumuller S, Scholl HP, Holz FG (2011) Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study. Am J Ophthalmol 151:876–886PubMedCrossRef Charbel Issa P, Finger RP, Kruse K, Baumuller S, Scholl HP, Holz FG (2011) Monthly ranibizumab for nonproliferative macular telangiectasia type 2: a 12-month prospective study. Am J Ophthalmol 151:876–886PubMedCrossRef
18.
Zurück zum Zitat Roller AB, Folk JC, Patel NM, Boldt HC, Russell SR, Abramoff MD, Mahajan VB (2011) Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia. Retina 31:1848–1855PubMedCrossRef Roller AB, Folk JC, Patel NM, Boldt HC, Russell SR, Abramoff MD, Mahajan VB (2011) Intravitreal bevacizumab for treatment of proliferative and nonproliferative type 2 idiopathic macular telangiectasia. Retina 31:1848–1855PubMedCrossRef
19.
Zurück zum Zitat Toy BC, Koo E, Cukras C, Meyerle CB, Chew EY, Wong WT (2012) Treatment of nonneovascular idiopathic macular telangiectasia type 2 with intravitreal ranibizumab: results of a phase II clinical trial. Retina 32:996–1006PubMedCrossRef Toy BC, Koo E, Cukras C, Meyerle CB, Chew EY, Wong WT (2012) Treatment of nonneovascular idiopathic macular telangiectasia type 2 with intravitreal ranibizumab: results of a phase II clinical trial. Retina 32:996–1006PubMedCrossRef
20.
Zurück zum Zitat Wolf-Schnurrbusch UE, Ceklic L, Brinkmann CK, Iliev ME, Frey M, Rothenbuehler SP, Enzmann V, Wolf S (2009) Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments. Investig Ophthalmol Vis Sci 50:3432–3437CrossRef Wolf-Schnurrbusch UE, Ceklic L, Brinkmann CK, Iliev ME, Frey M, Rothenbuehler SP, Enzmann V, Wolf S (2009) Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments. Investig Ophthalmol Vis Sci 50:3432–3437CrossRef
21.
Zurück zum Zitat Gass JD, Blodi BA (1993) Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology 100:1536–1546PubMed Gass JD, Blodi BA (1993) Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study. Ophthalmology 100:1536–1546PubMed
22.
Zurück zum Zitat Gass JD, Oyakawa RT (1982) Idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol 100:769–780PubMedCrossRef Gass JD, Oyakawa RT (1982) Idiopathic juxtafoveolar retinal telangiectasis. Arch Ophthalmol 100:769–780PubMedCrossRef
23.
Zurück zum Zitat Watzke RC, Klein ML, Folk JC, Farmer SG, Munsen RS, Champfer RJ, Sletten KR (2005) Long-term juxtafoveal retinal telangiectasia. Retina 25:727–735PubMedCrossRef Watzke RC, Klein ML, Folk JC, Farmer SG, Munsen RS, Champfer RJ, Sletten KR (2005) Long-term juxtafoveal retinal telangiectasia. Retina 25:727–735PubMedCrossRef
24.
Zurück zum Zitat Shukla D, Gupta SR, Neelakantan N, Tiwari S, Gupta S, Patwardhan AR, Soubhya TB (2012) Type 2 idiopathic macular telangiectasia. Retina 32:265–274PubMedCrossRef Shukla D, Gupta SR, Neelakantan N, Tiwari S, Gupta S, Patwardhan AR, Soubhya TB (2012) Type 2 idiopathic macular telangiectasia. Retina 32:265–274PubMedCrossRef
25.
Zurück zum Zitat Chew EY (2006) Parafoveal teleaniectasis. In: Ryan SJ, Hinton DR, Schachat AP, Wilkinson CP (eds) Retina. Mosby, St. Louis, pp 1409–1415CrossRef Chew EY (2006) Parafoveal teleaniectasis. In: Ryan SJ, Hinton DR, Schachat AP, Wilkinson CP (eds) Retina. Mosby, St. Louis, pp 1409–1415CrossRef
26.
Zurück zum Zitat Charbel Issa P, Troeger E, Finger R, Holz FG, Wilke R, Scholl HP (2010) Structure-function correlation of the human central retina. PLoS One 5:e12864PubMedCrossRef Charbel Issa P, Troeger E, Finger R, Holz FG, Wilke R, Scholl HP (2010) Structure-function correlation of the human central retina. PLoS One 5:e12864PubMedCrossRef
27.
Zurück zum Zitat Clemons TE, Gillies MC, Chew EY, Bird AC, Peto T, Figueroa MJ, Harrington MW (2010) Baseline characteristics of participants in the natural history study of macular telangiectasia (MacTel) MacTel Project Report No. 2. Ophthalmic Epidemiol 17:66–73PubMedCrossRef Clemons TE, Gillies MC, Chew EY, Bird AC, Peto T, Figueroa MJ, Harrington MW (2010) Baseline characteristics of participants in the natural history study of macular telangiectasia (MacTel) MacTel Project Report No. 2. Ophthalmic Epidemiol 17:66–73PubMedCrossRef
Metadaten
Titel
Long-term course in type 2 idiopathic macular telangiectasia
verfasst von
Tobias Meyer-ter-Vehn
Sina Herzog
Marc Schargus
Winfried Göbel
Rainer Guthoff
Publikationsdatum
01.11.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 11/2013
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-013-2346-z

Weitere Artikel der Ausgabe 11/2013

Graefe's Archive for Clinical and Experimental Ophthalmology 11/2013 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Open Access 22.02.2024 | Peeling | Originalien

Selektive Vitalfarbstoffe in der Makulachirurgie

Erhöhen sie die Wahrscheinlichkeit der intraoperativen ILM-Identifizierung auch bei einem erfahrenen Operateur?

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.